Prospective Assessment of Quality of Life (QOL) in Pediatric Patients Treated With Radiation Therapy for Brain Tumors and Non-central Nervous System (Non-CNS) Malignancies
1 other identifier
observational
600
1 country
1
Brief Summary
In recent years, remarkable advances in medical oncology, surgery, and radiology have allowed for increasing cure rates for childhood malignancies. This success has led to an emerging understanding of the kinds of effects that treatments can have on the pediatric population and how such effects can influence pediatric cancer survivor's functioning and quality of life. It has become tremendously important to assess the long-term complications due to therapy in this growing sector of survivors and to tailor our treatments so as to minimize these late effects. The Investigators at MGH are committed to improving the delivery of radiotherapy to our patients and improving the outcome for these patients. MGH has an on-site cyclotron for proton radiotherapy in order to provide the most advanced care for patients in need. Proton therapy possesses a clinical advantage over standard photon therapy in that its optimal dose distribution delivers the bulk of radiation to the tumor site. This method spares the greatest volume of normal tissue, resulting in decreased short-term and long-term morbidity. Through open pediatric protocols for patients treated with proton radiotherapy, the investigators aim to define and report the acute and late effects associated with treatment. The investigators also treat a number of patients off-protocol with both proton and photon radiotherapy, and are interested in reporting these patients' QOL outcomes in conjunction with other clinical data that may be pertinent to the site of tumor treatment. This research is significant in that it will allow us to delineate the positive and negative effects of radiation treatment on patients' QOL, highlighting points of success and exposing areas that are in need of improvement. Such knowledge will be used to improve the experience of pediatric cancer survivors in the future. The aims of this study are: 1) to prospectively collect and report the QOL outcomes in patients treated with radiotherapy and 2) to correlate the QOL data with pertinent clinical information.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Sep 2005
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
September 1, 2005
CompletedFirst Submitted
Initial submission to the registry
April 30, 2010
CompletedFirst Posted
Study publicly available on registry
May 4, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2027
ExpectedStudy Completion
Last participant's last visit for all outcomes
March 1, 2029
May 13, 2026
May 1, 2026
21.8 years
April 30, 2010
May 11, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Assessment of Quality of Life
Longitudinal description of quality of life outcomes in patients treated with radiation therapy
10 years
Secondary Outcomes (1)
Correlation of QOL data with clinical information
10 years
Study Arms (1)
Pediatric patients treated with radiotherapy
Interventions
Quality of Life surveys (no treatment)
Eligibility Criteria
Patients coming to MGH for radiation therapy with curative intent.
You may qualify if:
- Any patient being treated with radiation therapy with curative intent
- Patients between the ages of 2 and 25
- Patients who speak either English or Spanish
- Patients who agree to fill out the questionnaire
You may not qualify if:
- Patients younger than 2 years of age or over 25
- Patients receiving treatment with palliative intent
- Patients who do not wish to participate
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Torunn Yock, MD
Massachusetts General Hospital
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Director, Pediatric Radiation Oncology
Study Record Dates
First Submitted
April 30, 2010
First Posted
May 4, 2010
Study Start
September 1, 2005
Primary Completion (Estimated)
June 1, 2027
Study Completion (Estimated)
March 1, 2029
Last Updated
May 13, 2026
Record last verified: 2026-05